Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Late Toxicities in Pediatric Cancer Care

TOP - August 2015, Vol 8, No 3 - Pediatric Cancer
Meg Barbor, MPH

“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime,” said Kerry Parsons, PharmD, at the recent Hematology/Oncology Pharmacy Association annual conference.

“We always have to think about the toxicities that we’ve introduced into these patients, and how we can try to prevent them or clean them up after that,” she said.

Childhood Cancer Facts

New diagnoses of pediatric cancer (young children and adolescent populations) represent 1% of all newly diagnosed cancers across the United States population, or about 20,000 new cases per year, stated Dr Parsons, a pediatric hematology/oncology pharmacist at Children’s of Alabama in Birmingham.

In young children, about half of malignancies are represented by acute lymphoblastic leukemia and brain tumors, at 26% and 21%, respectively. In adolescents up to age 19, there is much more variability. In that population, Hodgkin lymphoma is the most frequently occurring cancer, and brain tumors are still in the top one-third of malignancies, said Dr Parsons.

“We also notice an emergence in what we might typically consider to be adult cancers,” she said, especially thyroid cancer and melanoma.

Late Toxicities in Patients with Childhood Cancer

“Risk factors for late effects in childhood cancer survivors are variable, but commonsensical based on what we know about toxicities,” said Dr Parsons.

More than 60% experience at least one late effect while 27% experience a late effect that is severe or life threatening. Risk factors are related to the type and location of the cancer, the area of the body treated, genetics, and the child’s age when treated.

Cardiovascular effects are most often correlated with exposure to radiation and anthracyclines. Incidence of secondary malignant neoplasms within the first 20 to 30 years after diagnosis ranges from 3% to 21%, and is associated with factors such as radiation and high-risk chemotherapy exposure. Endocrine disorders are seen in 40% to 60% of patients treated for cancer in childhood.

“Cognitive effects are a persistent deficit in childhood cancer survivors,” Dr Parsons stated. “Deficits will vary significantly based on the underlying diagnosis for the patient, and these effects are associated with the survivor’s ability to hold a job, achieve at least a median level of education, and to be able to live independently of their parents.”

Obstacles to Survivorship Care

“Lifestyle behaviors are going to contribute to some of the late tox­icities that we’ve observed in childhood cancer survivors,” Dr Parsons noted. These behaviors include regular tobacco use, heavy alcohol consumption, lack of physical activity, and lack of healthcare utilization.

“Any pediatric cancer patient across the board has about a 75% chance of long-term survival,” she said. “We had over 80% survival in the most recent decade across all cancer diagnoses, and this is a testament to the multi-institutional cooperative group research efforts across the nation and even across the globe. The mission to better understand childhood cancer survivorship is very much alive and well.”

Reference
Sivik J, Iacovelli L, Scarpace S, et al. Practice panel: survivorship. Presented at: 11th Hematology/Oncology Pharmacy Association Annual Conference; March 25-28, 2015; Austin, TX.

Related Items
Engaging Patients in Their Cancer Care Through Digital Health
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Neurofeedback Reduces Symptoms of CIPN
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
NCI-COG Pediatric MATCH Trial Shows High Rate of Targetable Molecular Alterations
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pediatric Cancer
The Evolving Role of Precision Medicine in Clinical Practice
Meg Barbor, MPH
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in HOPA
New HOPA Committee Aims to Improve Patient Outreach Services
Meg Barbor, MPH
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in HOPA
Current Strategies in the Management of CINV
Meg Barbor, MPH
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in HOPA
Applying Business Principles to Everyday Practice
Meg Barbor, MPH
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in HOPA
Targeted Intervention Reduces Opioid Use by Nearly 50% After Urologic Oncology Surgery
Meg Barbor, MPH
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Symptom Management
Last modified: September 9, 2019